# A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors

> **NCT03565445** · PHASE1 · COMPLETED · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 190 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** ASP1948
- **DRUG:** nivolumab
- **DRUG:** pembrolizumab

## Key facts

- **NCT ID:** NCT03565445
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-02
- **Primary completion:** 2023-03-27
- **Final completion:** 2023-03-27
- **Target enrollment:** 190 (ACTUAL)
- **Last updated:** 2024-11-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03565445

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03565445, "A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT03565445. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*